These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

463 related articles for article (PubMed ID: 11505404)

  • 1. Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group.
    Shepherd FA; Dancey J; Arnold A; Neville A; Rusthoven J; Johnson RD; Fisher B; Eisenhauer E
    Cancer; 2001 Aug; 92(3):595-600. PubMed ID: 11505404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pemetrexed: a multitargeted antifolate.
    Rollins KD; Lindley C
    Clin Ther; 2005 Sep; 27(9):1343-82. PubMed ID: 16291410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and pharmacokinetic phase I study of multitargeted antifolate (LY231514) in combination with cisplatin.
    Thödtmann R; Depenbrock H; Dumez H; Blatter J; Johnson RD; van Oosterom A; Hanauske AR
    J Clin Oncol; 1999 Oct; 17(10):3009-16. PubMed ID: 10506594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514, pemetrexed disodium, ALIMTA) and cisplatin: a multicenter phase II trial.
    Manegold C; Gatzemeier U; von Pawel J; Pirker R; Malayeri R; Blatter J; Krejcy K
    Ann Oncol; 2000 Apr; 11(4):435-40. PubMed ID: 10847462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: A phase II study. National Cancer Institute of Canada Clinical Trials Group.
    Rusthoven JJ; Eisenhauer E; Butts C; Gregg R; Dancey J; Fisher B; Iglesias J
    J Clin Oncol; 1999 Apr; 17(4):1194. PubMed ID: 10561178
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of the multitargeted antifolate LY231514 (ALIMTA, MTA, pemetrexed disodium) in patients with advanced pancreatic cancer.
    Miller KD; Picus J; Blanke C; John W; Clark J; Shulman LN; Thornton D; Rowinsky E; Loehrer PJ
    Ann Oncol; 2000 Jan; 11(1):101-3. PubMed ID: 10690396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.
    Paz-Ares L; de Marinis F; Dediu M; Thomas M; Pujol JL; Bidoli P; Molinier O; Sahoo TP; Laack E; Reck M; Corral J; Melemed S; John W; Chouaki N; Zimmermann AH; Visseren-Grul C; Gridelli C
    Lancet Oncol; 2012 Mar; 13(3):247-55. PubMed ID: 22341744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized phase II study of pemetrexed in combination with cisplatin or carboplatin as first-line therapy for patients with locally advanced or metastatic non-small-cell lung cancer.
    Schuette WH; Gröschel A; Sebastian M; Andreas S; Müller T; Schneller F; Guetz S; Eschbach C; Bohnet S; Leschinger MI; Reck M
    Clin Lung Cancer; 2013 May; 14(3):215-23. PubMed ID: 23332288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral vinorelbine plus cisplatin as first-line chemotherapy in nonsquamous non-small-cell lung cancer: final results of an International randomized phase II study (NAVotrial 01).
    Bennouna J; Havel L; Krzakowski M; Kollmeier J; Gervais R; Dansin E; Serke M; Favaretto A; Szczesna A; Cobo M; Ciuffreda L; Jassem J; Nicolini M; Ramlau R; Amoroso D; Melotti B; Almodovar T; Riggi M; Caux NR; Vaissière N; Tan EH
    Clin Lung Cancer; 2014 Jul; 15(4):258-65. PubMed ID: 24954228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term and low-grade safety results of a phase III study (PARAMOUNT): maintenance pemetrexed plus best supportive care versus placebo plus best supportive care immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer.
    Pujol JL; Paz-Ares L; de Marinis F; Dediu M; Thomas M; Bidoli P; Corral J; San Antonio B; Chouaki N; John W; Zimmermann A; Visseren-Grul C; Gridelli C
    Clin Lung Cancer; 2014 Nov; 15(6):418-25. PubMed ID: 25104617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II trial of pemetrexed disodium (ALIMTA, LY231514) in chemotherapy-naïve patients with advanced non-small-cell lung cancer.
    Clarke SJ; Abratt R; Goedhals L; Boyer MJ; Millward MJ; Ackland SP
    Ann Oncol; 2002 May; 13(5):737-41. PubMed ID: 12075742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.
    Scagliotti GV; Parikh P; von Pawel J; Biesma B; Vansteenkiste J; Manegold C; Serwatowski P; Gatzemeier U; Digumarti R; Zukin M; Lee JS; Mellemgaard A; Park K; Patil S; Rolski J; Goksel T; de Marinis F; Simms L; Sugarman KP; Gandara D
    J Clin Oncol; 2008 Jul; 26(21):3543-51. PubMed ID: 18506025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study.
    Paz-Ares L; Mezger J; Ciuleanu TE; Fischer JR; von Pawel J; Provencio M; Kazarnowicz A; Losonczy G; de Castro G; Szczesna A; Crino L; Reck M; Ramlau R; Ulsperger E; Schumann C; Miziara JE; Lessa ÁE; Dediu M; Bálint B; Depenbrock H; Soldatenkova V; Kurek R; Hirsch FR; Thatcher N; Socinski MA;
    Lancet Oncol; 2015 Mar; 16(3):328-37. PubMed ID: 25701171
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of pemetrexed and cisplatin plus cetuximab followed by pemetrexed and cetuximab maintenance therapy in patients with advanced nonsquamous non-small cell lung cancer.
    Schmid-Bindert G; Gebbia V; Mayer F; Arriola E; Márquez-Medina D; Syrigos K; Biesma B; Leschinger MI; Frimodt-Moller B; Ripoche V; Myrand SP; Nguyen TS; Hozak RR; Zimmermann A; Visseren-Grul C; Schuette W
    Lung Cancer; 2013 Sep; 81(3):428-434. PubMed ID: 23790468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pemetrexed and cisplatin as first-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) with asymptomatic inoperable brain metastases: a multicenter phase II trial (GFPC 07-01).
    Barlesi F; Gervais R; Lena H; Hureaux J; Berard H; Paillotin D; Bota S; Monnet I; Chajara A; Robinet G
    Ann Oncol; 2011 Nov; 22(11):2466-2470. PubMed ID: 21321089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sunitinib combined with pemetrexed and cisplatin: results of a phase I dose-escalation and pharmacokinetic study in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer and mesothelioma.
    Camidge DR; Blais N; Jonker DJ; Soulières D; Doebele RC; Ruiz-Garcia A; Thall A; Zhang K; Laurie SA; Chao RC; Chow LQ
    Cancer Chemother Pharmacol; 2013 Feb; 71(2):307-19. PubMed ID: 23108697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I and pharmacokinetic study of pemetrexed plus cisplatin in chemonaive patients with locally advanced or metastatic malignant pleural mesothelioma or non-small cell lung cancer.
    Dickgreber NJ; Fink TH; Latz JE; Hossain AM; Musib LC; Thomas M
    Clin Cancer Res; 2009 Jan; 15(1):382-9. PubMed ID: 19118069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A dose-escalation study of pemetrexed and docetaxel in non-small-cell lung cancer.
    Kotsakis A; Agelaki S; Vardakis N; Stathopoulos G; Vamvakas L; Kalykaki A; Kentepozidis N; Kontopodis E; Sfakiotaki G; Mavroudis D; Georgoulias V
    Cancer Chemother Pharmacol; 2011 Aug; 68(2):415-22. PubMed ID: 21069335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II study of paclitaxel-ifosfamide-cisplatin combination in advanced nonsmall cell lung carcinoma.
    Kosmas C; Tsavaris NB; Polyzos A; Kalofonos HP; Sepsas E; Malamos NA; Vadiaka M; Dosios T; Antonopoulos MJ
    Cancer; 2000 Aug; 89(4):774-82. PubMed ID: 10951340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I study of pemetrexed and cisplatin with concurrent high-dose thoracic radiation after induction chemotherapy in patients with unresectable locally advanced non-small cell lung cancer.
    Mornex F; Peignaux K; Germain T; Wautot V; Chouaki N; Bourayou N; Tourani JM
    Lung Cancer; 2013 Apr; 80(1):68-74. PubMed ID: 23332163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.